Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 8/20 | 0.52 |
| ▸ | ABL1 | P00519 | 8/20 | 0.52 |
| ▸ | SRC | P12931 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | YES1 | P07947 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | HCK | P08631 | 2/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | FGR | P09769 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | SIK2 | Q9H0K1 | 9/20 | 0.47 |
| ▸ | SIK3 | Q9Y2K2 | 9/20 | 0.47 |
| ▸ | SIK1 | P57059 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254631 | 0.90 | ABL1 (0.50) | LCKABL1SRCKITEGFR | |
| SCHEMBL12445981 | 0.90 | LCK (0.52) | LCKABL1SRCKITEGFR | |
| SCHEMBL20633817 | 0.90 | RAB9A (0.52) | LCKABL1SRCKITEGFR | |
| SCHEMBL22964566 | 0.87 | LCK (0.56) | LCKABL1SRCKITEGFR | |
| SCHEMBL4250766 | 0.85 | LCK (0.53) | LCKABL1SRCKITEGFR | |
| SCHEMBL14141859 | 0.84 | LCK (0.52) | LCKABL1SRCKITEGFR | |
| SCHEMBL14142362 | 0.84 | LCK (0.52) | LCKABL1SRCKITEGFR | |
| SCHEMBL19436377 | 0.84 | LCK (0.52) | LCKABL1SRCKITEGFR | |
| SCHEMBL21495194 | 0.84 | SIK2 (0.48) | LCKABL1SRCKITEGFR | |
| SCHEMBL22964561 | 0.84 | LCK (0.60) | LCKABL1SRCKITEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-12338440-B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | IOMX THERAPEUTICS AG (DE) | 2025-06-24 | — | — | US | disclosed |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-12-24 | — | — | US | disclosed |
| US-12139480-B2 | 5-thiazolecarboxamide kinase inhibitor and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-118369321-A | Synthetic schemes and procedures for preparing SIK3 inhibitors and intermediates thereof | 艾奥麦克斯治疗公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-102161660-A | Preparation method of 2-(6-chloro-2-methylpyrimidinyl-4-amino)-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide | INST MATERIA MEDICA CAMS | 2011-08-24 | — | — | CN | disclosed |
| WO-2011095125-A1 | SYNTHESIS METHODS AND PURIFICATION METHODS OF DASATINIB | 南京卡文迪许生物工程技术有限公司 (CN) | 2011-08-11 | — | — | WO | disclosed |
| CN-101106990-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2010-12-08 | — | — | CN | disclosed |
| CN-101845045-A | Novel method for synthesizing dasatinib | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD | 2010-09-29 | — | — | CN | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| CN-101106990-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-01-16 | — | — | CN | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| EP-1809299-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006047507-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | LCK, SRC, CILK1 | LCK 1/4885ABL1 8/4885SRC 2/4885 |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | LCK 56/4885ABL1 1/4885SRC 11/4885 |
| US-12139480-B2 | 5-thiazolecarboxamide kinase inhibitor and uses thereof | LCK, TEC, CILK1 | LCK 1/4885ABL1 7/4885SRC 6/4885 |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | LCK 1/4885ABL1 8/4885SRC 2/4885 |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | LCK 1/4885ABL1 8/4885SRC 2/4885 |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | SIK3, SIK1, SIK2 | LCK 769/4885ABL1 1145/4885SRC 1963/4885 |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | LCK 359/4885ABL1 1088/4885SRC 859/4885 |
| US-12338440-B2 | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | SIK3, SIK1, SIK2 | LCK 359/4885ABL1 1088/4885SRC 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.